• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

新型基础胰岛素的未来

Future of newer basal insulin.

作者信息

Madhu S V, Velmurugan M

机构信息

Department of Medicine, Division of Endocrinology and Metabolism, University College of Medical Sciences and Guru Teg Bahadur Hospital, New Delhi, India.

出版信息

Indian J Endocrinol Metab. 2013 Mar;17(2):249-53. doi: 10.4103/2230-8210.109690.

DOI:10.4103/2230-8210.109690
PMID:23776897
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3683199/
Abstract

Basal insulin have been developed over the years. In recent times newer analogues have been added to the armanentarium for diabetes therapy. This review specifically reviews the current status of different basal insulins.

摘要

多年来已研发出基础胰岛素。近年来，新型类似物已被纳入糖尿病治疗药物库中。本综述专门回顾了不同基础胰岛素的现状。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c7f9/3683199/a7718335afd4/IJEM-17-249-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c7f9/3683199/85ddeead7005/IJEM-17-249-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c7f9/3683199/4bbfe0791fd9/IJEM-17-249-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c7f9/3683199/5fc896354b62/IJEM-17-249-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c7f9/3683199/a7718335afd4/IJEM-17-249-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c7f9/3683199/85ddeead7005/IJEM-17-249-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c7f9/3683199/4bbfe0791fd9/IJEM-17-249-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c7f9/3683199/5fc896354b62/IJEM-17-249-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c7f9/3683199/a7718335afd4/IJEM-17-249-g004.jpg

相似文献

1
Future of newer basal insulin.新型基础胰岛素的未来
Indian J Endocrinol Metab. 2013 Mar;17(2):249-53. doi: 10.4103/2230-8210.109690.
2
Basal insulin analogues in the treatment of diabetes mellitus: What progress have we made?基础胰岛素类似物在糖尿病治疗中的应用：我们取得了哪些进展？
Indian J Endocrinol Metab. 2015 Apr;19(Suppl 1):S71-3. doi: 10.4103/2230-8210.155407.
3
The past, present, and future of basal insulins.基础胰岛素的过去、现在和未来。
Diabetes Metab Res Rev. 2016 Sep;32(6):478-96. doi: 10.1002/dmrr.2763. Epub 2015 Nov 25.
4
Understanding how pharmacokinetic and pharmacodynamic differences of basal analog insulins influence clinical practice.了解基础胰岛素类似物的药代动力学和药效学差异如何影响临床实践。
Curr Med Res Opin. 2017 Oct;33(10):1821-1831. doi: 10.1080/03007995.2017.1335192. Epub 2017 Jun 23.
5
Degludec: a novel basal insulin.德谷胰岛素：一种新型基础胰岛素。
Recent Pat Endocr Metab Immune Drug Discov. 2012 Jan;6(1):18-23. doi: 10.2174/187221412799015326.
6
Considerations for Insulin-Treated Type 2 Diabetes Patients During Hospitalization: A Narrative Review of What We Need to Know in the Age of Second-Generation Basal Insulin Analogs.胰岛素治疗的2型糖尿病患者住院期间的注意事项：关于第二代基础胰岛素类似物时代我们需要了解的内容的叙述性综述
Diabetes Ther. 2020 Dec;11(12):2775-2790. doi: 10.1007/s13300-020-00920-z. Epub 2020 Sep 30.
7
Clinical relevance of pharmacokinetic and pharmacodynamic profiles of insulin degludec (100, 200 U/mL) and insulin glargine (100, 300 U/mL) - a review of evidence and clinical interpretation.胰岛素地特胰岛素（100、200 U/mL）和甘精胰岛素（100、300 U/mL）的药代动力学和药效学特征的临床相关性-证据回顾与临床解读。
Diabetes Metab. 2019 Sep;45(4):330-340. doi: 10.1016/j.diabet.2018.11.004. Epub 2018 Nov 26.
8
The development of new basal insulins: is there any clinical advantage with their use in type 2 diabetes?新型基础胰岛素的研发：在 2 型糖尿病患者中应用这类胰岛素是否具有临床优势？
Expert Opin Biol Ther. 2014 Jun;14(6):799-808. doi: 10.1517/14712598.2014.895812. Epub 2014 Mar 27.
9
Cost-effectiveness of switching to insulin degludec from other basal insulins: evidence from Swedish real-world data.从其他基础胰岛素转换为德谷胰岛素的成本效益：来自瑞典真实世界数据的证据。
Curr Med Res Opin. 2017 Apr;33(4):647-655. doi: 10.1080/03007995.2016.1277194. Epub 2017 Jan 20.
10
Switching to Degludec is Associated with Reduced Hypoglycaemia, Irrespective of Definition Used or Patient Characteristics: Secondary Analysis of the ReFLeCT Prospective, Observational Study.改用德谷胰岛素与低血糖发生率降低相关，无论采用何种定义或患者特征如何：ReFLeCT前瞻性观察性研究的二次分析
Diabetes Ther. 2020 Sep;11(9):2159-2167. doi: 10.1007/s13300-020-00875-1. Epub 2020 Jul 14.

引用本文的文献

1
Time-action profiles of insulin degludec in healthy dogs and its effects on glycemic control in diabetic dogs.德谷胰岛素在健康犬中的时效曲线及其对糖尿病犬血糖控制的影响。
J Vet Med Sci. 2018 Nov 23;80(11):1720-1723. doi: 10.1292/jvms.17-0714. Epub 2018 Oct 11.
2
Soluble insulin analogs combining rapid- and long-acting hypoglycemic properties - From an efficient E. coli expression system to a pharmaceutical formulation.兼具速效和长效降血糖特性的可溶性胰岛素类似物——从高效大肠杆菌表达系统到药物制剂
PLoS One. 2017 Mar 15;12(3):e0172600. doi: 10.1371/journal.pone.0172600. eCollection 2017.

本文引用的文献

1
Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long).在 2 型糖尿病的胰岛素初治患者中，德谷胰岛素对比甘精胰岛素：一项为期 1 年、随机、以目标为导向的试验（BEGIN Once Long）。
Diabetes Care. 2012 Dec;35(12):2464-71. doi: 10.2337/dc12-1205. Epub 2012 Oct 5.
2
Basal insulin and cardiovascular and other outcomes in dysglycemia.基础胰岛素与糖调节受损患者的心血管及其他结局。
N Engl J Med. 2012 Jul 26;367(4):319-28. doi: 10.1056/NEJMoa1203858. Epub 2012 Jun 11.
3
Insulins: past, present, and future.
胰岛素：过去、现在和未来。
Endocrinol Metab Clin North Am. 2012 Mar;41(1):1-24. doi: 10.1016/j.ecl.2012.03.002. Epub 2012 Apr 12.
4
Degludec: a novel basal insulin.德谷胰岛素：一种新型基础胰岛素。
Recent Pat Endocr Metab Immune Drug Discov. 2012 Jan;6(1):18-23. doi: 10.2174/187221412799015326.
5
Insulin preparations with prolonged effect.长效胰岛素制剂。
Diabetes Technol Ther. 2011 Jun;13 Suppl 1:S5-14. doi: 10.1089/dia.2011.0068.
6
Long-term effects of insulin glargine on the risk of breast cancer.甘精胰岛素长期治疗对乳腺癌发病风险的影响。
Diabetologia. 2011 Sep;54(9):2254-62. doi: 10.1007/s00125-011-2190-9. Epub 2011 May 26.
7
The future of basal insulin supplementation.基础胰岛素补充的未来。
Diabetes Technol Ther. 2011 Jun;13 Suppl 1:S103-8. doi: 10.1089/dia.2010.0251. Epub 2011 May 13.
8
A new-generation ultra-long-acting basal insulin with a bolus boost compared with insulin glargine in insulin-naive people with type 2 diabetes: a randomized, controlled trial.与甘精胰岛素相比，新代超长效基础胰岛素联合餐时胰岛素注射治疗初诊 2 型糖尿病患者的随机对照研究。
Diabetes Care. 2011 Mar;34(3):669-74. doi: 10.2337/dc10-1905. Epub 2011 Feb 1.
9
Insulin degludec in type 1 diabetes: a randomized controlled trial of a new-generation ultra-long-acting insulin compared with insulin glargine.德谷胰岛素治疗 1 型糖尿病：新一代超长效胰岛素与甘精胰岛素的随机对照试验。
Diabetes Care. 2011 Mar;34(3):661-5. doi: 10.2337/dc10-1925. Epub 2011 Jan 26.
10
Long-acting insulin analogues elicit atypical signalling events mediated by the insulin receptor and insulin-like growth factor-I receptor.长效胰岛素类似物通过胰岛素受体和胰岛素样生长因子-I 受体介导非典型信号事件。
Diabetologia. 2010 Dec;53(12):2667-75. doi: 10.1007/s00125-010-1899-1. Epub 2010 Sep 12.